바이오인

 

The annual 2013 Pharmaceutical Industry Profile provides an overview of the sector, highlighting the latest medical advances, the impact of biopharmaceutical companies on the economy and the future of innovation.

 

 

Introduction
v Committed to Patients, Health, and the Economy

 

1 Impacting Patients
4 Progress Against Disease
9 The Evolving Value of Medicines

 

11 Improving the Quality and Value of Health Care
12 Better Use of Medicines Improves Outcomes
13 The Economic Value of Better Use of Medicines
14 Gaps in Optimal Use of Medicines
16 Improving Use of Medicines

19 Supporting the Economy
22 Boosting State and Regional Economies
23 Ripple Effect of Industry R&D Support

29 R&D: Delivering Innovation
32 Overview of the R&D Process
36 The Evolving R&D Process
40 Understanding the Nature of Progress and Innovation

 

43 A Promising Pipeline
44 Examining the Pipeline

51 Looking Ahead
52 Higher Hurdles
52 Meeting Challenges

 

54 Conclusion
54 Committed to Progress

55 Appendix
56 PhRMA: Who We Are
56 Our Mission
57 PhRMA Member Companies: Full Members & Research Associate Members
60 PhRMA Annual Membership Survey: Definition of Terms
62 List of Tables: Detailed Results from the PhRMA Annual Membership Survey

 

 

New medicines have been an important part of transforming many diseases in recent years.

They are putting rheumatoid arthritis into remission, greatly increasing the chances of survival for children with cancer, curing hepatitis in many patients, and reducing hospitalizations for HIV patients.

The biopharmaceutical industry is a dynamic, knowledge-driven sector.The work of its researchers bring hope to millions of patients and benefits to local and national economies. Biopharmaceutical companies invest heavily in research and development; in the past year, Pharmaceutical Research and Manufacturers of America (PhRMA) members surpassed the $500 billion mark in research and development (R&D) spending since 2000.

Developing a new medicine is challenging and the chances of success are extremely low, particularly in recent years. The 43 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2012 represented the highest total in 15 years, a proud landmark for an industry whose mission is to save and improve lives.

In addition to their health benefits, medicines are an important part of the solution to rising health care costs through their role in reducing the need for hospital stays, surgeries, and other costly interventions. The biopharmaceutical sector also supports hundreds of thousands of high-quality, well-paying jobs in the United States that contribute significantly to the health of our communities and the nation’s economy.

The 2013 Biopharmaceutical Research Industry Profile provides an overview of the essential contributions the industry makes to the lives and health of people and to the U.S. economy. Chapter 1 examines the enormous value of medicines developed by
biopharmaceutical companies for patients around the world.

Chapter 2 discusses the role that preion medicines play in improving the quality and value of health care, and in controlling its cost. Chapter 3 describes the impact of the biopharmaceutical industry on local, state, and the national economies. Chapter 4 captures the R&D process that brings us new medicines. Chapter 5 reflects on our growing knowledge
of disease, which is providing the most promising platform ever for developing new medicines and new ways to save lives. And Chapter 6 looks ahead at the hurdles facing the sector and how biopharmaceutical companies are meeting those challenges.

 

 

........(계속)